Drug Trial Radar · NCT05144997
Lorlatinib Continuation Study
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
76
Actual
Start
Dec 28, 2021
Primary completion
Oct 25, 2029
Study completion Oct 25, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention
Conditions
- Non-Small-Cell Lung Cancer
- NSCLC
Interventions
LorlatinibDrug
ALK-positive NSCL treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events leading to permanent discontinuation of study interventionTime frame: Baseline up to approximately 5 years
- Number of serious adverse events reported for all participantsTime frame: Baseline up to approximately 5 years
Locations
27 sites in 8 countries. Site status is shown where the registry gives one.
Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California
Fudan University Shanghai Cancer Center
Shanghai, China
The First affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Hunan Provincial Tumor Hospital
Changsha, Hunan, China
General Hospital of Eastern Theater Command
Nanjing, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
The first hospital of jilin university
Changchun, Jilin, China
Sir Run Shaw Hospital
Hangzhou, Qiantang District, China
The Second Affiliated Hospital of PLA Air Force Medical University
Xi'an, Shaanxi, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Sichuan Cancer hospital
Chengdu, Sichuan, China
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Zhejiang University College of Medicine
Hangzhou, Zhejiang, China
CHU de Rennes - Hôpital Pontchaillou
Rennes, France
Institut Gustave Roussy
Villejuif, France
Healthcare Global Enterprises
Bengaluru, Karnataka, India
Bhaktivedanta Hospital & Research Institute
Thane, Maharashtra, India
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
National University Hospital
Singapore, Singapore
National Cancer Centre Singapore
Singapore, Singapore
Hospital Universitari Vall d'Hebron
Barcelona, BARCELONA, Spain
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.